Blog
RSS FeedPosted by Michael Wonder on 04 Jun 2025
DoH publishes revised agenda for May 2025 PBAC meeting in June!
4 June 2025 - The DoH has published a revised agenda for last month's PBAC meeting. ...
Posted by Michael Wonder on 05 Apr 2025
Trump Administration rejects expanding Medicare, Medicaid coverage of obesity drugs
4 April 2025 - Biden Administration had proposed late last year coverage of the popular medicines for obesity. ...
Posted by Michael Wonder on 17 Feb 2025
Cost sharing for preferred branded drugs in Medicare Part D
14 February 2025 - Most individuals in the US are concerned about prescription drug affordability. ...
Posted by Michael Wonder on 02 Feb 2025
Cell and gene therapies - improving access and outcomes for Medicare and Medicaid beneficiaries
1 February 2025 - State Medicaid agencies can now apply to participate in a new model that supports voluntary, outcomes-based agreements ...
Posted by Michael Wonder on 19 Jan 2025
Ozempic among the next drugs up for Medicare price negotiations
17 January 2025 - List of drugs account for $41 billion in annual Medicare spending, Biden administration says. ...
Posted by Michael Wonder on 24 Dec 2024
HHS announces cost savings for 64 prescription drugs thanks to the Medicare Prescription Drug Inflation Rebate Program established by the Biden-Harris Administration’s lower cost prescription drug law
20 December 2024 - Under the Inflation Reduction Act, some people with Medicare will pay less for some Part B ...
Posted by Michael Wonder on 07 Dec 2024
Biden-Harris Administration takes next steps to increase access to sickle cell disease treatments
4 December 2024 - Today, the Biden-Harris Administration announced that two drug manufacturers with FDA approved gene therapies for sickle ...
Posted by Michael Wonder on 04 Dec 2024
Biden-Harris Administration announces Medicare Advantage and Medicare Part D prescription drug proposals that aim to improve care and access for enrollees
26 November 2024 - Today, the CMS is proposing actions in the Medicare Advantage and Medicare Part D prescription drug programs ...
Posted by Michael Wonder on 15 Nov 2024
Representativeness of studies required under Medicare’s coverage with evidence development program
13 November 2024 - Medicare beneficiaries are often inadequately represented in clinical studies supporting US Food and Drug Administration medical product ...
Posted by Michael Wonder on 13 Nov 2024
The sickest patients are fleeing private Medicare plans costing taxpayers billions
11 November 2024 - Medicare Advantage patients in the last year of life were far more likely to switch to traditional ...
Posted by Michael Wonder on 01 Nov 2024
I’m the director of the Center for Medicare. Here’s how we executed the first round of drug price negotiation.
29 October 2024 - The historic Inflation Reduction Act of 2022 has fundamentally improved the affordability of and access to prescription ...
Posted by Michael Wonder on 18 Oct 2024
Alhemo recommended for European approval as first once daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
18 October 2024 - Novo Nordisk today announced that the EMA's CHMP has adopted a positive opinion, recommending approval of ...
Posted by Michael Wonder on 17 Oct 2024
Medicare’s first round of drug price negotiation - measuring success
16 October 2024 - The Federal Government has proven that it can navigate the difficult process of identifying drugs for price ...
Posted by Michael Wonder on 14 Sep 2024
A roadmap for improving Medicare’s application of coverage with evidence development
13 September 2024 - The Centers for Medicare and Medicaid Services’ coverage with evidence development policy allows the agency to provide ...
Posted by Michael Wonder on 04 Aug 2024
How to tell if Biden drove a hard bargain in Medicare drug price negotiations
30 July 2024 - The deadline for announcing how much Medicare lowered drug prices in the first year of negotiation is ...